CRSP Stock Overview
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
CRISPR Therapeutics AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$55.51 |
| 52 Week High | US$86.95 |
| 52 Week Low | US$38.94 |
| Beta | 1.65 |
| 1 Month Change | 17.58% |
| 3 Month Change | 13.45% |
| 1 Year Change | -9.06% |
| 3 Year Change | -2.61% |
| 5 Year Change | 38.39% |
| Change since IPO | 293.97% |
Recent News & Updates
Recent updates
Companies Like CRISPR Therapeutics (NASDAQ:CRSP) Are In A Position To Invest In Growth
Dec 08
CRISPR CAR T cell therapy for skin/blood cancer gets FDA regenerative medicine tag
Sep 28Crispr: Elucidating And Forecasting Key Developments
Sep 21Crispr Therapeutics: Nearing Harvest Season
Sep 08Crispr Therapeutics: Unlikely To Fall To May Lows, But Not The Time To Buy Yet (Technical Analysis)
Aug 25News Flash: Analysts Just Made A Noticeable Upgrade To Their CRISPR Therapeutics AG (NASDAQ:CRSP) Forecasts
Aug 09CRISPR Therapeutics GAAP EPS of -$2.40 misses by $0.19, revenue of $0.16M misses by $2.04M
Aug 08Crispr Therapeutics' Continued Progress Warrants A Buy
Jul 25Crispr Therapeutics: Innovation Day Showcases Upside Opportunities In Short And Long Term
Jun 23Crispr Therapeutics: Progress, Risk, And Reward
Apr 27The Commercial Potential Of Crispr In Light Of Patent Challenges
Mar 22Bad News may be Good for Long Term Investors - Analyzing the Key Risks of CRISPR Therapeutics AG (NASDAQ:CRSP)
Mar 10CRISPR Therapeutics - Progress Adds More Value Than Patent Setback Subtracts
Mar 03CRISPR Therapeutics AG's (NASDAQ:CRSP) Intrinsic Value Is Potentially 99% Above Its Share Price
Feb 02Crispr Therapeutics' Giant Leap For Humankind
Jan 14Crispr Therapeutics: Buy The Dip On Promise Of Vertex Collaboration
Dec 15Crispr Therapeutics: An Interesting Company That Has Reconnected With A Fair Valuation
Dec 02CRISPR's Life-Saving Technology Has Massive Potential
Nov 22Crispr Therapeutics: The Future Of Gene Therapy
Oct 15Crispr: Bad News For Gene Editing
Sep 18Crispr Therapeutics: Lucrative Partnerships And Promising Data Increase Its Appeal
Aug 28Do CRISPR Therapeutics's (NASDAQ:CRSP) Earnings Warrant Your Attention?
Aug 04Crispr Therapeutics: Get Ready To Bail Out
Jul 05CRISPR Therapeutics and Capsida Biotherapeutics ink strategic collaboration agreement
Jun 15Here's Why Shareholders May Want To Be Cautious With Increasing CRISPR Therapeutics AG's (NASDAQ:CRSP) CEO Pay Packet
Jun 04CRISPR: First Cut Has Deepest Value - Buy And Hold
May 31Intellia and Sangamo preferred as RBC extends gene editing coverage
May 04We're Hopeful That CRISPR Therapeutics (NASDAQ:CRSP) Will Use Its Cash Wisely
Apr 29Crispr Therapeutics: Strong Partnership And Data Development
Apr 26How Many CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Do Institutions Own?
Mar 14Investors Who Bought CRISPR Therapeutics (NASDAQ:CRSP) Shares Three Years Ago Are Now Up 411%
Jan 20
CRISPR Is The Future Of Medicine, And CRSP Is One Stock To Own
Dec 22Need To Know: Analysts Are Much More Bullish On CRISPR Therapeutics AG (NASDAQ:CRSP) Revenues
Dec 16CRISPR Therapeutics enters into a share sale agreement with Jefferies
Dec 11Shareholder Returns
| CRSP | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 8.8% | -0.8% | 0.9% |
| 1Y | -9.1% | 3.9% | -10.9% |
Return vs Industry: CRSP underperformed the US Biotechs industry which returned 3.9% over the past year.
Return vs Market: CRSP exceeded the US Market which returned -10.9% over the past year.
Price Volatility
| CRSP volatility | |
|---|---|
| CRSP Average Weekly Movement | 8.6% |
| Biotechs Industry Average Movement | 12.0% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: CRSP is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: CRSP's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 473 | Sam Kulkarni | https://www.crisprtx.com |
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases.
CRISPR Therapeutics AG Fundamentals Summary
| CRSP fundamental statistics | |
|---|---|
| Market Cap | US$4.35b |
| Earnings (TTM) | -US$680.85m |
| Revenue (TTM) | US$14.09m |
308.4x
P/S Ratio-6.4x
P/E RatioIs CRSP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRSP income statement (TTM) | |
|---|---|
| Revenue | US$14.09m |
| Cost of Revenue | US$593.32m |
| Gross Profit | -US$579.23m |
| Other Expenses | US$101.62m |
| Earnings | -US$680.85m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -8.70 |
| Gross Margin | -4,110.66% |
| Net Profit Margin | -4,831.79% |
| Debt/Equity Ratio | 0% |
How did CRSP perform over the long term?
See historical performance and comparison